Abstract

ANTI-OBESITY MEDICATIONS AND CARDIOMETABOLIC EFFECTS: A MODERN REVIEW

Fariya Sultana*

ABSTRACT

Obesity is an international public health emergency that has serious consequences for cardiovascular disease, diabetes, and metabolic syndrome. Conventional interventions for weight loss are usually inadequate in decreasing cardiometabolic risk. The availability of new antiobesity medications, including glucagon-like peptide-1 (GLP-1) receptor agonists like semaglutide and dual incretin receptor agonists like tirzepatide, heralds a new era in the treatment of obesity. These agents not only achieve substantial weight reduction but also confer significant cardiovascular protection. This review explores their pharmacological mechanisms, clinical trial data, and implications for evolving treatment guidelines, highlighting future directions in integrated cardiometabolic care.

Keywords: .